Alicia S Kunin-Batson1,2, Xiaomin Lu2,3, Lyn Balsamo4, Kelsey Graber5, Meenakshi Devidas3, Stephen P Hunger6, William L Carroll7, Naomi J Winick8, Leonard A Mattano9, Kelly W Maloney10, Nina S Kadan-Lottick4. 1. HealthPartners Institute, Minneapolis, Minnesota. 2. Division of Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota. 3. Department of Biostatistics, Colleges of Medicine, Public Health, and Health Professions, University of Florida, Gainesville, Florida. 4. Department of Pediatric Hematology/Oncology, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, Connecticut. 5. Yale University Child Study Center, New Haven, Connecticut. 6. Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 7. Department of Pediatrics, New York University Langone Medical Center, Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, New York, New York. 8. Department of Pediatric Hematology/Oncology, University of Texas Southwestern School of Medicine, Dallas, Texas. 9. HARP Pharma Consulting, Mystic, Connecticut. 10. Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado.
Abstract
BACKGROUND: The months immediately after the completion of treatment for childhood acute lymphoblastic leukemia (ALL) are often regarded as a stressful time for children and families. In this prospective, longitudinal study, the prevalence and predictors of anxiety and depressive symptoms after the completion of treatment were examined. METHODS: Participants included 160 children aged 2 to 9 years with standard-risk ALL who were enrolled on Children's Oncology Group protocol AALL0331. Parents completed standardized rating scales of their children's emotional-behavioral functioning and measures of coping and family functioning at approximately 1 month, 6 months, and 12 months after diagnosis and again 3 months after the completion of chemotherapy. RESULTS: At 3 months off therapy, approximately 24% of survivors had at-risk/clinically elevated anxiety scores and 28% had elevated depression scores, which are significantly higher than the expected 15% in the general population (P = .028 and .001, respectively). Patients with elevated anxiety 1 month after diagnosis were at greater risk of off-therapy anxiety (odds ratio, 4.1; 95% confidence interval, 1.31-12.73 [P = .022]) and those with elevated depressive symptoms 6 months after diagnosis were at greater risk of off-therapy depression (odds ratio, 7.88; 95% confidence interval, 2.61-23.81 [P = .0002]). In adjusted longitudinal analyses, unhealthy family functioning (P = .008) and less reliance on social support coping (P = .009) were found to be associated with risk of emotional distress. Children from Spanish-speaking families (P = .05) also were found to be at a greater risk of distress. CONCLUSIONS: A significant percentage of children experience emotional distress during and after therapy for ALL. These data provide a compelling rationale for targeted early screening and psychosocial interventions to support family functioning and coping skills. Cancer 2016;122:1608-17.
BACKGROUND: The months immediately after the completion of treatment for childhood acute lymphoblastic leukemia (ALL) are often regarded as a stressful time for children and families. In this prospective, longitudinal study, the prevalence and predictors of anxiety and depressive symptoms after the completion of treatment were examined. METHODS:Participants included 160 children aged 2 to 9 years with standard-risk ALL who were enrolled on Children's Oncology Group protocol AALL0331. Parents completed standardized rating scales of their children's emotional-behavioral functioning and measures of coping and family functioning at approximately 1 month, 6 months, and 12 months after diagnosis and again 3 months after the completion of chemotherapy. RESULTS: At 3 months off therapy, approximately 24% of survivors had at-risk/clinically elevated anxiety scores and 28% had elevated depression scores, which are significantly higher than the expected 15% in the general population (P = .028 and .001, respectively). Patients with elevated anxiety 1 month after diagnosis were at greater risk of off-therapy anxiety (odds ratio, 4.1; 95% confidence interval, 1.31-12.73 [P = .022]) and those with elevated depressive symptoms 6 months after diagnosis were at greater risk of off-therapy depression (odds ratio, 7.88; 95% confidence interval, 2.61-23.81 [P = .0002]). In adjusted longitudinal analyses, unhealthy family functioning (P = .008) and less reliance on social support coping (P = .009) were found to be associated with risk of emotional distress. Children from Spanish-speaking families (P = .05) also were found to be at a greater risk of distress. CONCLUSIONS: A significant percentage of children experience emotional distress during and after therapy for ALL. These data provide a compelling rationale for targeted early screening and psychosocial interventions to support family functioning and coping skills. Cancer 2016;122:1608-17.
Authors: Laura K Campbell; Mary Scaduto; Deborah Van Slyke; Frances Niarhos; James A Whitlock; Bruce E Compas Journal: J Pediatr Psychol Date: 2008-07-30
Authors: Yousif Matloub; Bruce C Bostrom; Stephen P Hunger; Linda C Stork; Anne Angiolillo; Harland Sather; Mei La; Julie M Gastier-Foster; Nyla A Heerema; Scott Sailer; Patrick J Buckley; Blythe Thomson; Catherine Cole; James B Nachman; Gregory Reaman; Naomi Winick; William L Carroll; Meenakshi Devidas; Paul S Gaynon Journal: Blood Date: 2011-05-11 Impact factor: 22.113
Authors: Olle Jane Z Sahler; Diane L Fairclough; Sean Phipps; Raymond K Mulhern; Michael J Dolgin; Robert B Noll; Ernest R Katz; James W Varni; Donna R Copeland; Robert W Butler Journal: J Consult Clin Psychol Date: 2005-04
Authors: William F Pirl; Jesse R Fann; Joseph A Greer; Ilana Braun; Teresa Deshields; Caryl Fulcher; Elizabeth Harvey; Jimmie Holland; Vicki Kennedy; Mark Lazenby; Lynne Wagner; Meghan Underhill; Deborah K Walker; James Zabora; Bradley Zebrack; Wayne A Bardwell Journal: Cancer Date: 2014-05-02 Impact factor: 6.860
Authors: Wendy L Hobbie; Susan K Ogle; Maureen Reilly; Jill P Ginsberg; Mary Rourke; Sarah Ratcliffe; Janet A Deatrick Journal: J Pediatr Oncol Nurs Date: 2010 Jul-Aug Impact factor: 1.636
Authors: Alexis L Johns; Alyssa A Oland; Ernest R Katz; Olle Jane Z Sahler; Martha A Askins; Robert W Butler; Michael J Dolgin Journal: J Pediatr Oncol Nurs Date: 2009-04-27 Impact factor: 1.636
Authors: Soo Jin Yoon; Kyong-Mee Chung; Jung Woo Han; Seung Min Hahn; Sun Hee Kim; Chuhl Joo Lyu Journal: Support Care Cancer Date: 2019-02-25 Impact factor: 3.603
Authors: Hilary A Marusak; Allesandra S Iadipaolo; Shelley Paulisin; Felicity W Harper; Jeffrey W Taub; Kristopher Dulay; Farrah Elrahal; Craig Peters; Kelsey Sala-Hamrick; Laura M Crespo; Christine A Rabinak Journal: Pediatr Blood Cancer Date: 2018-09-30 Impact factor: 3.167
Authors: Mary C Hooke; Michelle A Mathiason; Audrey Blommer; Jessica Hutter; Pauline Mitby; Olga Taylor; Michael E Scheurer; Alicia S Kunin-Batson; Wei Pan; Marilyn J Hockenberry Journal: Cancer Nurs Date: 2022 Mar-Apr 01 Impact factor: 2.592
Authors: Cinzia R De Luca; Melissa Mulraney; Vicki Anderson; Peter Downie; Winn Ma; Maria C McCarthy Journal: J Clin Psychol Med Settings Date: 2022-02-03